{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:16:11Z","timestamp":1760242571799,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":3567,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.exphem.2012.05.007","type":"journal-article","created":{"date-parts":[[2012,5,24]],"date-time":"2012-05-24T13:32:33Z","timestamp":1337866353000},"page":"724-737.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["CML cells expressing the TEL\/MDS1\/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737"],"prefix":"10.1016","volume":"40","author":[{"given":"Kazuyuki","family":"Shimada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Minami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte K.","family":"Hind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S.","family":"Cragg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Naoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2012.05.007_bib1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2012.05.007_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1084\/jem.181.1.307","article-title":"Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene","volume":"181","author":"Sawyers","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2012.05.007_bib3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V86.2.726.bloodjournal862726","article-title":"Phosphatidylinositol-3 kinase activity is regulated by BCR\/ABL and is required for the growth of Philadelphia chromosome-positive cells","volume":"86","author":"Skorski","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.007_bib4","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2012.05.007_bib5","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2012.05.007_bib6","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2012.05.007_bib7","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"suppl 3","key":"10.1016\/j.exphem.2012.05.007_bib8","first-page":"S5","article-title":"Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry","volume":"17","author":"Horowitz","year":"1996","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 1","key":"10.1016\/j.exphem.2012.05.007_bib9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/10428194.2010.546920","article-title":"Mechanisms of resistance to BCR-ABL kinase inhibitors","volume":"52","author":"Diamond","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2012.05.007_bib10","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2012.05.007_bib11","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1182\/blood-2003-03-0993","article-title":"Functional consequence of MDR1 expression on imatinib intracellular concentrations","volume":"102","author":"Widmer","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.007_bib12","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.007_bib13","doi-asserted-by":"crossref","first-page":"34227","DOI":"10.1074\/jbc.M402290200","article-title":"A Bcr\/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2","volume":"279","author":"Dai","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2012.05.007_bib14","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.007_bib15","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia","volume":"94","author":"Holyoake","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.007_bib16","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood.V97.3.720","article-title":"Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in\u00a0vitro in association with up-regulation of expression of interleukin-3","volume":"97","author":"Holyoake","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.007_bib17","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/asheducation-2007.1.384","article-title":"The biology of CML blast crisis","author":"Radich","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.exphem.2012.05.007_bib18","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2002-05-1459","article-title":"High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients","volume":"101","author":"Barjesteh van Waalwijk van Doorn-Khosrovani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.007_bib19","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/j.1460-2075.1994.tb06288.x","article-title":"Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia","volume":"13","author":"Mitani","year":"1994","journal-title":"EMBO J"},{"key":"10.1016\/j.exphem.2012.05.007_bib20","first-page":"1849","article-title":"Overexpression of Evi-1 and dysmegakaryopoiesis in human leukemias: reply to Carapeti, Goldman and Cross, Leukemia 1996;10:1561","volume":"10","author":"Ogawa","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2012.05.007_bib21","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1182\/blood.V84.8.2681.2681","article-title":"Identification of a breakpoint cluster region 3' of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26)","volume":"84","author":"Suzukawa","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.007_bib22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ajh.10028","article-title":"Expression of the TEL\/EVI1 fusion transcript in a patient with chronic myelogenous leukemia with t(3;12)(q26;p13)","volume":"69","author":"Nakamura","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2012.05.007_bib23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.stem.2008.06.002","article-title":"Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells","volume":"3","author":"Goyama","year":"2008","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2012.05.007_bib24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/27945","article-title":"The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3","volume":"394","author":"Kurokawa","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2012.05.007_bib25","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1093\/emboj\/19.12.2958","article-title":"The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death","volume":"19","author":"Kurokawa","year":"2000","journal-title":"EMBO J"},{"key":"10.1016\/j.exphem.2012.05.007_bib26","doi-asserted-by":"crossref","first-page":"24020","DOI":"10.1016\/S0021-9258(19)51041-9","article-title":"Evi-1 raises AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain","volume":"269","author":"Tanaka","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2012.05.007_bib27","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2012.05.007_bib28","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.bbrc.2006.05.047","article-title":"Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in\u00a0vivo","volume":"345","author":"Atsumi","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.exphem.2012.05.007_bib29","first-page":"5480","article-title":"CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts","volume":"63","author":"Chan","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2012.05.007_bib30","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1038\/sj.leu.2402558","article-title":"Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors","volume":"16","author":"Minami","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2012.05.007_bib31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/sj.cdd.4400627","article-title":"Complement mediated cell death is associated with DNA fragmentation","volume":"7","author":"Cragg","year":"2000","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.exphem.2012.05.007_bib32","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","article-title":"Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance","volume":"113","author":"Hiraga","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.007_bib33","first-page":"564","article-title":"Fusion of ETV6 to MDS1\/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders","volume":"57","author":"Peeters","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2012.05.007_bib34","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1073\/pnas.0606176103","article-title":"Bim and Bad mediate imatinib-induced killing of Bcr\/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic","volume":"103","author":"Kuroda","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2012.05.007_bib35","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2012.05.007_bib36","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1182\/blood-2009-12-261602","article-title":"Evi1 represses PTEN expression and activates PI3K\/AKT\/mTOR via interactions with polycomb proteins","volume":"117","author":"Yoshimi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.007_bib37","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc2615","article-title":"Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics","volume":"9","author":"Cragg","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2012.05.007_bib38","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/cdd.2008.137","article-title":"Bcl-2 inhibitors: small molecules with a big impact on cancer therapy","volume":"16","author":"Vogler","year":"2009","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.exphem.2012.05.007_bib39","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2012.05.007_bib40","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2012.05.007_bib41","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","article-title":"Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors","volume":"29","author":"Gandhi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2012.05.007_bib42","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.semcancer.2005.01.008","article-title":"ETV6: a versatile player in leukemogenesis","volume":"15","author":"Bohlander","year":"2005","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.exphem.2012.05.007_bib43","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1349-7006.2009.01152.x","article-title":"Pathogenetic significance of ecotropic viral integration site-1 in hematological malignancies","volume":"100","author":"Goyama","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1016\/j.exphem.2012.05.007_bib44","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1158\/1535-7163.MCT-09-1012","article-title":"MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in\u00a0vitro and in\u00a0vivo","volume":"9","author":"Hirai","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.exphem.2012.05.007_bib45","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.cancergen.2011.06.002","article-title":"Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors","volume":"204","author":"Paquette","year":"2011","journal-title":"Cancer Genet"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X12001828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X12001828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:30:23Z","timestamp":1759566623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X12001828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0301472X12001828"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2012.05.007","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CML cells expressing the TEL\/MDS1\/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2012.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}